Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00693758
Other study ID # 18798
Secondary ID 18798
Status Completed
Phase Phase 0
First received December 10, 2007
Last updated October 2, 2011
Start date January 2006
Est. completion date September 2011

Study information

Verified date October 2011
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The ability of a new SSFP-based BOLD MRI sequence to assess myocardial oxygenation changes in response to coronary flow changes induced by adenosine and increased CO2-partial pressure will be examined in healthy volunteers and patients with suspected coronary artery disease. Also the susceptibility of a new SSFP-based BOLD sensitive MRI sequence to changes in arterial oxygenation will be examined. This will help understand the physiologic basis of oxygen sensitive imaging of the heart.


Description:

A new SSFP based T2 and T2* sensitive sequence which provides good BOLD contrast will be used. It was developed by researchers at the Stephenson CMR Centre and Northwestern University of Chicago. Its major advantage to previous BOLD sensitive sequences is its lower susceptibility to motion artifacts.

MR imaging is performed with a commercial 1.5 T Siemens MR scanner (Siemens Avanto). In order to obtain a homogeneous magnetic field an additional surface chest coil is used in combination to the body coil. Three short axis views representing basal, mid and apical slices are set up and are used throughout the study. If the volunteer has to be moved from their position for any reason, similar short axis views will be attempted.

In order to improve and further develop the MRI sequence the technique will be used in a arm-cuff model in healthy volunteers, using reactive hyperemia, which is easier to image than the heart. The BOLD-MRI signal intensity of the forearm will be assessed during a short, 3 min. lasting upper arm-cuff occlusion and the following reactive hyperemia.

Main interest of the study is the examination of the heart of healthy volunteers as well as patients with suspected coronary heart disease with this BOLD-MRI technique. The signal intensity of the myocardium at rest and after different coronary flow stimulation will be assessed. These stimuli will be pharmacologic (adenosine) as well as changes in arterial CO2 and O2 pressure.

All subjects that will undergo changes in their breathing gases, will first be examined in the vascular research laboratory of Dr. M. Poulin. There the subjects will be familiarized with the modified end-tidal forcing system (MEFS) and their individual response to changes in breathing gases will be assessed. A complete dry-run of the breathing protocol will be performed including 2 capillary blood gas analysis. On a second day subjects will be studied in the temperature-controlled MR scanning room at Stephenson CMR Centre in a fasting state for the previous 4 hours. This includes refrain from caffeine and nicotine in these preceding 4 hours. Prior to baseline scanning, capillary blood will be sampled from the finger for blood gas, hemoglobin and hematocrit analysis. Thereafter, the volunteer will be connected to the MEFS. A baseline scan will then be performed comprising of localization, cine imaging, cross sectional flow measurement of the coronary sinus (CS) and BOLD MRI of three representative short axis slices. Then an intravenous adenosine infusion will be started. After 3 min. MR scan will be repeated. After 5 min. of rest another baseline will be recorded. Then successively the carbon dioxide pressure will be increased in two steps to 40 and 45 mmHg. After a resting period of 5 min, another baseline scan will be performed. Then oxygen partial pressure of the inspired air will be reduced in 3 steps as described in the following paragraph until an inspiratory oxygen partial pressure of 45 mmHg is achieved. This will reflect an arterial oxygen saturation of approximately 90, 85 and 80%. At each step, BOLD MRI (3 axial slices) and cross sectional flow measurements of CS will be performed. Following 5 minutes of rest another baseline scan will be performed. Throughout experimentation the subject will be connected to the METFS and we will measure ventilation, blood pressure (noninvasive), heart rate (electrocardiogram) and arterial oxygen saturation (pulse oximetry).

Image-analysis: A region of interest will be drawn around the myocardium of each short axis. The averaged signal intensity is assessed and compared to baseline after adenosine infusion and at the different levels of arterial oxygenation and carbon dioxide concentration. Additionally, differential analysis for subendocardium and subepicardium will be performed.

Coronary flow in the coronary sinus will be calculated using phase contrast MRI. This technique was first described by van Rossum, validated in phantoms and animal studies and successfully used in human patient studies. Because of the relatively small diameter of the CS, absolute flow values may not be very accurate; therefore the relative change between different levels of hypoxia will be calculated.

End-points:

BOLD SI in the myocardium defined as the averaged signal intensity of the myocardium.

Relative flow changes in CS to baseline.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Informed written consent

- age > 18 years

- no known cardiovascular disease and no vasoactive medication (if recruited as healthy volunteer)

- suspected coronary artery disease or microvascular dysfunction (if recruited as patient)

- no known obstructive or restrictive lung disease

- fasting for 4 hours prior to the study

Exclusion Criteria:

- Contraindications for MRI

- Known obstructive or restrictive lung disease

- concomitant serious medical condition

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Drug:
adenosine
intravenous infusion of adenosine (140microgr./min/kg)
Other:
modified end-tidal forcing system
changes in partial pressures of O2 and CO2 in inspired air
arm cuff occlusion
3 min. lasting upper arm cuff occlusion
Device:
Breathing gas
Changes in pO2 and pCO2 in inspired air mix
Blood pressure cuff
supra-systolic arm occlusion with pressure cuff

Locations

Country Name City State
Canada Stephenson CMR Centre at Foothills Medical Centre, University of Calgary Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary BOLD-MRI signal intensity changes 60 No
Secondary Flow changes 60 min No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Completed NCT01434043 - Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging